These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 36368608)

  • 1. Approaches of formulation bridging in support of orally administered drug product development.
    Han M; Xu J; Lin Y
    Int J Pharm; 2022 Dec; 629():122380. PubMed ID: 36368608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physiologically Based Biopharmaceutics Modeling for Gefapixant IR Formulation Development and Defining the Bioequivalence Dissolution Safe Space.
    Wang M; Heimbach T; Zhu W; Wu D; Reuter KG; Kesisoglou F
    AAPS J; 2024 Jun; 26(4):69. PubMed ID: 38862807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Applications of Physiologically Based Biopharmaceutics Modeling (PBBM) to Support Drug Product Quality: A Workshop Summary Report.
    Mitra A; Suarez-Sharp S; Pepin XJH; Flanagan T; Zhao Y; Kotzagiorgis E; Parrott N; Sharan S; Tistaert C; Heimbach T; Zolnik B; Sjögren E; Wu F; Anand O; Kakar S; Li M; Veerasingham S; Kijima S; Lima Santos GM; Ning B; Raines K; Rullo G; Mandula H; Delvadia P; Dressman J; Dickinson PA; Babiskin A
    J Pharm Sci; 2021 Feb; 110(2):594-609. PubMed ID: 33152375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physiologically Based Pharmacokinetics Modeling in Biopharmaceutics: Case Studies for Establishing the Bioequivalence Safe Space for Innovator and Generic Drugs.
    Wu D; Sanghavi M; Kollipara S; Ahmed T; Saini AK; Heimbach T
    Pharm Res; 2023 Feb; 40(2):337-357. PubMed ID: 35840856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dissolution and Translational Modeling Strategies Toward Establishing an In Vitro-In Vivo Link-a Workshop Summary Report.
    Heimbach T; Suarez-Sharp S; Kakhi M; Holmstock N; Olivares-Morales A; Pepin X; Sjögren E; Tsakalozou E; Seo P; Li M; Zhang X; Lin HP; Montague T; Mitra A; Morris D; Patel N; Kesisoglou F
    AAPS J; 2019 Feb; 21(2):29. PubMed ID: 30746576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Best Practices in the Development and Validation of Physiologically Based Biopharmaceutics Modeling. A Workshop Summary Report.
    Parrott N; Suarez-Sharp S; Kesisoglou F; Pathak SM; Good D; Wagner C; Dallmann A; Mullin J; Patel N; Riedmaier AE; Mitra A; Raines K; Butler J; Kakhi M; Li M; Zhao Y; Tsakalozou E; Flanagan T; Dressman J; Pepin X
    J Pharm Sci; 2021 Feb; 110(2):584-593. PubMed ID: 33058891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of Extended-Release Formulations Containing Cyclobenzaprine Based on Physiologically Based Biopharmaceutics Modeling and Bioequivalence Safe Space.
    Miranda Dos Santos E; Ferraz HG; Issa MG; Duque MD
    J Pharm Sci; 2023 Dec; 112(12):3131-3140. PubMed ID: 37473918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Use of Physiologically Based Pharmacokinetic Analyses-in Biopharmaceutics Applications -Regulatory and Industry Perspectives.
    Anand O; Pepin XJH; Kolhatkar V; Seo P
    Pharm Res; 2022 Aug; 39(8):1681-1700. PubMed ID: 35585448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Novel Approach to Justify Dissolution Differences in an Extended Release Drug Product using Physiologically Based Biopharmaceutics Modeling and Simulation.
    Aishwarya R; Murthy A; Ahmed T; Chachad S
    J Pharm Sci; 2022 Jun; 111(6):1820-1832. PubMed ID: 35217007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current State and Challenges of Physiologically Based Biopharmaceutics Modeling (PBBM) in Oral Drug Product Development.
    Wu D; Li M
    Pharm Res; 2023 Feb; 40(2):321-336. PubMed ID: 36076007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishing the Bioequivalence Safe Space for Immediate-Release Oral Dosage Forms using Physiologically Based Biopharmaceutics Modeling (PBBM): Case Studies.
    Heimbach T; Kesisoglou F; Novakovic J; Tistaert C; Mueller-Zsigmondy M; Kollipara S; Ahmed T; Mitra A; Suarez-Sharp S
    J Pharm Sci; 2021 Dec; 110(12):3896-3906. PubMed ID: 34551349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physiologically Based Biopharmaceutics Modeling to Demonstrate Virtual Bioequivalence and Bioequivalence Safe-space for Ribociclib which has Permeation Rate-controlled Absorption.
    Laisney M; Heimbach T; Mueller-Zsigmondy M; Blumenstein L; Costa R; Ji Y
    J Pharm Sci; 2022 Jan; 111(1):274-284. PubMed ID: 34678270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Physiologically Based Biopharmaceutics Modeling (PBBM) in Fed Bioequivalence Study Waivers: Regulatory Outlook, Case Studies and Future Perspectives.
    Kollipara S; Martins FS; Sanghavi M; Santos GML; Saini A; Ahmed T
    J Pharm Sci; 2024 Feb; 113(2):345-358. PubMed ID: 38043684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine.
    Jantratid E; Prakongpan S; Amidon GL; Dressman JB
    Clin Pharmacokinet; 2006; 45(4):385-99. PubMed ID: 16584285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acalabrutinib Maleate Tablets: The Physiologically Based Biopharmaceutics Model behind the Drug Product Dissolution Specification.
    Pepin X; McAlpine V; Moir A; Mann J
    Mol Pharm; 2023 Apr; 20(4):2181-2193. PubMed ID: 36859819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The importance of dissolution for orally inhaled drug products: pharmaceutical, regulatory, and clinical considerations.
    Somby K; Hingle M; Tomic I; Forbes B
    Expert Opin Drug Deliv; 2023; 20(8):1033-1036. PubMed ID: 37078605
    [No Abstract]   [Full Text] [Related]  

  • 17. Physiologically Based Absorption Modeling to Impact Biopharmaceutics and Formulation Strategies in Drug Development-Industry Case Studies.
    Kesisoglou F; Chung J; van Asperen J; Heimbach T
    J Pharm Sci; 2016 Sep; 105(9):2723-2734. PubMed ID: 26886317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PBPK Absorption Modeling: Establishing the In Vitro-In Vivo Link-Industry Perspective.
    Stillhart C; Pepin X; Tistaert C; Good D; Van Den Bergh A; Parrott N; Kesisoglou F
    AAPS J; 2019 Jan; 21(2):19. PubMed ID: 30673891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Towards Virtual Bioequivalence Studies for Oral Dosage Forms Containing Poorly Water-Soluble Drugs: A Physiologically Based Biopharmaceutics Modeling (PBBM) Approach.
    Kambayashi A; Dressman JB
    J Pharm Sci; 2022 Jan; 111(1):135-145. PubMed ID: 34390740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Applications of Modeling and Simulation Approaches in Support of Drug Product Development of Oral Dosage Forms and Locally Acting Drug Products: a Symposium Summary.
    Tsakalozou E; Mohamed MF; Polak S; Heimbach T
    AAPS J; 2023 Oct; 25(6):96. PubMed ID: 37783902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.